SYRE
HEALTHCARESpyre Therapeutics Inc.
AI Insight
What's Moving SYRE Today?
No stock-specific AI insight has been generated for SYRE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$14.00$102.06
$83.95
Fundamentals
Market Cap$8.7B
P/E Ratio—
EPS$-2.12
Dividend Yield—
Dividend / Share—
ROE-31.1%
Profit Margin—
Debt / Equity—
Trading
Volume2.8M
Avg Volume (10D)—
Shares Outstanding86.8M
SYRE News
33 articles- Spyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE)Advfn·Jun 24, 2026
- Director at Spyre Therapeutics (SYRE) sells 20,000 shares under 10b5-1 planStock Titan·Jun 24, 2026
- Spyre (SYRE) fund converts Series B preferred, then exits common stakeStock Titan·Jun 24, 2026
- Spyre Therapeutics director Henderson sells $2 million in stock By Investing.comInvesting.com Nigeria·Jun 24, 2026
- Form 4 Spyre Therapeutics Inc For: 23 June By Investing.comInvesting.com Canada·Jun 24, 2026
- SYRE Maintained by Deutsche Bank -- Price Target Raised to $135GuruFocus·Jun 23, 2026
- Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis PatientsYahoo Finance·Jun 15, 2026
- Spyre Therapeutics Announces Grants of Inducement AwardsYahoo Finance·Jun 5, 2026
- SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock UpYahoo Finance·Jun 4, 2026
- Spyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside PotentialYahoo Finance·Jun 4, 2026
- Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics Inc (SYRE)GuruFocus·Jun 4, 2026
- Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpAYahoo Finance·Jun 3, 2026
- Why Spyre Therapeutics (SYRE) Is Down 6.1% After Broadening Its SPY003 Paragon License TermsYahoo Finance·Jun 2, 2026
- [Form 4] Spyre Therapeutics, Inc. Insider Trading ActivityStock Titan·May 30, 2026
- Spyre Therapeutics (SYRE) awards director 8,026 options at $72.51Stock Titan·May 30, 2026
- Spyre Therapeutics (SYRE) director receives option grant for 8,026 sharesStock Titan·May 30, 2026
- Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in SharesMotley Fool·May 17, 2026
- Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More SharesMotley Fool·May 17, 2026
- This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 MillionMotley Fool·May 17, 2026
- This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 MillionMotley Fool·May 17, 2026
- Hot Picks: Biotech stocks gain on cancer drugs and trial dataBNN Bloomberg·May 11, 2026
- Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive OfficerYahoo Finance·May 5, 2026
- Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 5, 2026
- Spyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million RaiseYahoo Finance·May 1, 2026
- Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?Yahoo Finance·Apr 30, 2026
- Spyre Therapeutics (SYRE): Favorite Stock of Elite Money ManagersYahoo Finance·Apr 27, 2026
- Here’s What Raymond James Says About Spyre Therapeutics Inc (SYRE)Yahoo Finance·Apr 23, 2026
- Spyre (SYRE) Climbs 42% as Treatment Candidate Poses ‘Best-in-Class’ PotentialYahoo Finance·Apr 20, 2026
- Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 MillionYahoo Finance·Apr 16, 2026
- Spyre Therapeutics (SYRE) Is Up 32.7% After $403 Million Equity Raise On Positive Phase 2 DataYahoo Finance·Apr 16, 2026
- Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common StockGlobeNewswire Inc.·Apr 15, 2026
- Spyre Therapeutics Announces Proposed Public Offering of its Common StockBenzinga·Apr 13, 2026
- Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis PatientsGlobeNewswire Inc.·Apr 13, 2026
All 33 articles loaded
Price Data
Open$83.22
Previous Close$97.05
Day High$88.15
Day Low$81.65
52 Week High$102.06
52 Week Low$14.00
52-Week Range
$14.00$102.06
$83.95
Fundamentals
Market Cap$8.7B
P/E Ratio—
EPS$-2.12
Dividend Yield—
Dividend / Share—
ROE-31.1%
Profit Margin—
Debt / Equity—
Trading
Volume2.8M
Avg Volume (10D)—
Shares Outstanding86.8M
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company is headquartered in Waltham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—